Finer Market Points' ASX Podcast
Connecting leading market themes and top performing ASX companies for better trading.
FMP follows the ethos the best performing shares don’t climb those massive gains alone, the move in packs. Huge performance gains from shares happen with the participation of other companies within the same industry. Lithium stocks, Uranium Stocks and Defence companies all rise off the back of their competitor’s strong announcements.
ASX investors and traders seeking to connect the best shares through their industries will find the standard and out own, unique industries grouped on FMP. The best performances on the ASX happen in concert with their peers and that’s what Shares In Play delivers through the Top 6 updates.
Subscribe to the channel to keep across:
-The ASX Top performing shares and industries
-Tuesday’s Technical analysis reports with Gary Glover
- The 30:30 List of top performing companies and the next market leaders
Finer Market Points' ASX Podcast
Breakthrough Therapies: How ASX Innovation Leaders Are Riding the Global Biotech Renaissance
This week's episode explores the ASX therapeutic innovation sector experiencing extraordinary momentum, featuring six breakthrough companies: Nyrada (NYR) with a stunning 123% quarterly and 189% yearly surge following clinical trial progressions, Mesoblast (MSB) delivering 189% yearly gains after achieving the first-ever FDA stem cell therapy approval, Bioxyne (BXN) up 228% over twelve months with its diversified pharmaceutical manufacturing platform, Aroa Biosurgery (ARX) advancing wound healing innovations, Neuren Pharmaceuticals (NEU) maintaining leadership in neurodevelopmental treatments, and Biome Australia (BIO) capitalising on the probiotic therapeutics trend.
The discussion covers how global money is rotating from AI into healthcare, creating a 3-5 year innovation cycle that's benefiting ASX companies developing everything from regenerative medicines to neurodevelopmental treatments. We analyse how regulatory momentum is accelerating, with companies successfully executing US-first, then international expansion strategies.
Key themes include FDA approval breakthroughs validating new therapeutic categories, European market expansion opportunities, and increasing pharmaceutical partnership activity. The episode reveals why this sector offers diversified exposure to the most promising areas of modern medicine, from commercialised success stories to high-potential development opportunities.
Disclaimer: This is not advice, seek professional assistance before acting on this information. AI and human resources have been used to generate this content from sources believed to be accurate.
Disclaimer: Finer Market Points Pty Ltd, CAR 1304002, AFSL 526688, ABN 87 645 284 680 (FMP) is incorporated in Australia with limited liability. FMP and affiliated entities may have commercial or financial interests in the companies or products mentioned. This information is directed and available to and for the benefit of Australian residents only and is not an advertisement, recommendation, forecast or advice. As this information has been prepared without considering your objectives, financial or taxation situation or needs, you should consider, before acting on this material, consider its appropriateness to your circumstances and seek appropriate professional advice. FMP and its related entities do not accept any liability for any loss or damages arising out of or in relation to the use of all or any part of this information. We believe that this information is correct as at the time of its compilation, but no warranty is made as to its accuracy, reliability, or completeness. This information is published solely for informational purposes and is not to be constructed as a solicitation or an offer to buy, sell or hold any securities, financial instruments or services in any jurisdiction. This information is under copyright to FMP and may not be used without prior consent.
